Tislelizumab in People With Colorectal Cancer

The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.

Trial Details

NCT ID
NCT06529523
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Tislelizumab
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Idi Araba, Lagos, Nigeria|6.52028,3.35382
  • Ile-Ife, Nigeria|7.4824,4.56032

Key Eligibility Criteria

  • Age 18 years or older on date of signing informed consent
  • ECOG performance status of 0 or 1
  • Negative pregnancy test done within 72 hours prior to start of treatment for women of childbearing potential.
  • Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →